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Key Clinical Message
With around 500 cases published worldwide, pulmonary alveolar microlithiasis
is a rare disorder with an autosomal recessive pattern of inheritance. We show
for the first time that homozygous deletions encompassing the entire SCL34A2
can be associated with this rare genetic pulmonary disease.
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Introduction
We present a 20-year-old patient diagnosed with pul-
monary alveolar microlithiasis (PAM). SNP array revealed
a 195 kb homozygous deletion encompassing the entire
SLC34A2 gene, not reported previously in PAM. Our
findings underline that deletions of this gene should be
analyzed in patients with a clinical diagnosis of PAM.
Clinical Report
A 20-year-old woman without a relevant medical history
was referred to the hospital for analysis after her chest X-
ray suggested the presence of interstitial lung disease. She
was the fourth child of consanguineous Moroccan par-
ents. Her only complaint was mild exertional dyspnea.
Physical examination revealed no clubbing and no lym-
phadenopathy Fine crackles were heard over the basal
lung fields. Laboratory testing revealed no abnormalities.
She did not have a history of smoking and none of her
relatives had a history of pulmonary disease. She had
been vaccinated with BCG and had, to her knowledge,
not been in contact with people with tuberculosis. She
did not have pets and had no known exposure to pul-
monary allergens. She did not use any medication, home-
opathic medication. Pulmonary function testing showed a
restrictive pattern [Tiffenaeu index 89%] with a forced
vital capacity (FVC) of 2.12 L (56%), a total lung capacity
(TLC) of 3.59 L (70)%, and a diffusing capacity of carbon
monoxide divided by the alveolar volume (DLCO/VA) of
1.91 mmol/(min *kPA*L) (103%) the lung. High-resolu-
tion computed tomography (HRCT) showed septal and
subpleural linear calcifications leading to thickening of
the interlobular septa with calcified intralobular nodules,
most profound in the lower fields (Fig. 1). A bron-
choalveolar lavage showed intracellular calcification and a
transbronchial peripheral lung biopsy revealed lung tissue
with numerous calcified concrements in the alveolar
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space. Microbiological testing was negative, including
cultures for mycobacteria. These findings confirmed the
clinical diagnosis (PAM; OMIM #265100). Her parents
and siblings have no medical complaints and chest X-rays
of her parents were normal. Her siblings have not yet
been analyzed (Fig. 2).
Genetic Analyses
Total genomic DNA was extracted from blood using stan-
dard protocols and sent to the Acibadem laboratory in
Instanbul to test for mutations in the SLC34A2 gene. DNA
amplification was not successful after several attempts.
MLPA testing for the SLC34A2 gene was not available. Sub-
sequently, an Affymetrix Cytoscan HD SNP array was per-
formed using standard protocols. The relative DNA copy
numbers at the CNV loci were determined by comparison
of the normalized array signal intensity data for the pro-
band’s DNA sample against the HapMap270 reference file
provided by Affymetrix, using Nexus software (from Bio-
discovery, Hawthorne, California, USA) [1]. The SNP
probes showed multiple regions of homozygosity, confirm-
ing consanguinity. SLC34A2, the causative gene for PAM,
was located in a large region of homozygosity on chromo-
some 4. The log2 ratio of the CNV probes covering the
SLC34A2 gene indicated a homozygous deletion with a
maximal homozygously deleted region spanning ~195 kb
and encompassed the entire SLC34A2 gene. The deletion
did not contain any other MIM genes (Fig. 3).
Discussion
PAM is a rare disorder in which numerous fragments
(microliths) consisting of calcium phosphate gradually
accumulate in the alveoli throughout the lungs [2–4].
PAM is an autosomal recessive disorder caused by loss of
function mutations in the gene encoding type IIb
sodium-phosphate cotransporter, SCL34A2. The gene has
13 exons, the first of which is noncoding. The protein is
involved in phosphate homeostasis [3, 5]. Homozygous
loss of function mutations result in reduced phosphate
reuptake by type IIb sodium phosphate transporter in the
apical membrane of type II alveolar cells, resulting in cal-
cium phosphate chelation and microlith formation result-
ing in a typical radiological appearance. Most patients are
asymptomatic for years or even for decades after the diag-
nosis, which is often based on the incidental finding of a
“sandstorm-appearance” on a chest X-ray. The potentially
(A) (B)
Figure 1. (A) High-resolution computed tomography (HRCT) in lung window showing thickened interlobular septal lines with fine centrilobular
calcifications leading to diffuse increased density of the lung parenchyma. (B) HRCT in bone window highlighting the microlith deposition; most
pronounced in the middle lobe and mediobasal segment of the right lower lobe.
Figure 2. Transbronchial lung biopsy. Images show alveolar tissue
adjacent to bronchiolar mucosa. In the alveolar spaces, many calcified
concrements are seen in some areas surrounded by mild fibrotic
reaction or giant cell response. Findings are consistent with
pulmonary alveolar microlithiasis.
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lethal disease often follows a long-term progressive course
resulting in slowly deteriorating pulmonary functions.
The age at clinical onset in an extensive study of 300
individuals was highly variable (5–41 years) with a great
discrepancy between radiological findings and clinical
symptoms [2]. The condition usually evolved over a per-
iod of 10–20 years. Only around 500 cases have been
reported worldwide [4]. Currently, no clearly defined
treatment options are available with exception of lung
transplantation. In addition, clinical and radiological
improvements were reported in two patients with PAM
who were treated with bisphosphonates [6]. The reported
mutations in the SCL34A2-gene most commonly occur in
one of the exons with a predicted protein truncating
effect [7]. Only five different homozygous deletions and
one deletion plus insertion mutation have been described
so far [5, 7, 8]. The previously reported deletions were
three different single nucleotide deletions, one deletion of
186 nucleotides, and a 5.5 kb long deletion [5, 8]. We
describe the first homozygous whole gene deletion
detected by SNP array. This finding confirmed the clinical
diagnosis of PAM in the proband and enabled genetic
counseling and (presymptomatic) genetic testing in her
relatives. Our study confirms the occurrence of homozy-
gous SCL34A2- deletions associated with PAM, adds to
the mutation spectrum by presenting the first reported
homozygous whole gene deletion and underlines the
importance of including a SNP array when considering
this rare disease, especially in a consanguineous pedigree.
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